Troy S M, Lucki I, Peirgies A A, Parker V D, Klockowski P M, Chiang S T
Wyeth-Ayerst Research, Philadelphia, PA 19101, USA.
J Clin Pharmacol. 1995 Apr;35(4):410-9. doi: 10.1002/j.1552-4604.1995.tb04082.x.
To assess possible pharmacokinetic and pharmacodynamic interactions between the antidepressant venlafaxine and diazepam, a randomized, two-period, crossover study was conducted in 18 men. Multiple-dose venlafaxine (50 mg every 8 hours) or placebo (double-blind) was given for 10 days; on day 4 a single placebo dose (same appearance as diazepam capsule, single-blind) was given; and on day 5 a single dose of diazepam (10 mg) was given. Pharmacokinetic data indicated that diazepam had no significant effect on venlafaxine or O-desmethylvenlafaxine disposition. Diazepam pharmacokinetics were minimally changed in the presence of venlafaxine. Diazepam oral clearance (CL/f) increased slightly (24 +/- 8 versus 26 +/- 6 mL/h/kg; P = .007), volume of distribution (Vz/f) increased (0.85 +/- 0.28 versus 0.99 +/- 0.34 L/kg; P = .02), and AUC decreased (5973 +/- 2304 versus 5008 +/- 1354 ng.h/mL; P = .02). Venlafaxine did not alter desmethyldiazepam pharmacokinetics. Pharmacodynamic data showed a statistically significant diazepam-venlafaxine interaction for only one of the eight psychometric tests given. Critical flicker fusion slightly decreased (P = .01) between placebo-diazepam (37.85 +/- 3.28 Hz) and venlafaxine-diazepam (37.09 +/- 4.13 Hz) treatments. The observed pharmacokinetic and pharmacodynamic interactions between diazepam and venlafaxine were small and probably clinically insignificant.
为评估抗抑郁药文拉法辛与地西泮之间可能存在的药代动力学和药效学相互作用,对18名男性进行了一项随机、两阶段、交叉研究。多剂量文拉法辛(每8小时50毫克)或安慰剂(双盲)给药10天;在第4天给予单剂安慰剂(外观与地西泮胶囊相同,单盲);在第5天给予单剂地西泮(10毫克)。药代动力学数据表明,地西泮对文拉法辛或O-去甲基文拉法辛的处置无显著影响。在文拉法辛存在的情况下,地西泮的药代动力学变化极小。地西泮的口服清除率(CL/f)略有增加(分别为24±8与26±6毫升/小时/千克;P = 0.007),分布容积(Vz/f)增加(分别为0.85±0.28与0.99±0.34升/千克;P = 0.02),曲线下面积(AUC)降低(分别为5973±2304与5008±1354纳克·小时/毫升;P = 0.02)。文拉法辛未改变去甲地西泮的药代动力学。药效学数据显示,在八项心理测量测试中,仅一项测试显示地西泮与文拉法辛之间存在具有统计学意义的相互作用。在安慰剂-地西泮(37.85±3.28赫兹)与文拉法辛-地西泮(37.09±4.13赫兹)治疗之间,临界闪烁融合频率略有降低(P = 0.01)。观察到的地西泮与文拉法辛之间的药代动力学和药效学相互作用较小,可能在临床上无显著意义。